Division of Endocrinology, Metabolism and Clinical Nutrition, Medical College of Wisconsin, 9200 West Wisconsin Avenue, Milwaukee, WI 53226, USA.
Am J Cardiovasc Drugs. 2013 Jun;13(3):163-75. doi: 10.1007/s40256-013-0008-5.
Obesity is a global pandemic and with its rise, its associated co-morbidities are increasing in prevalence, particularly uncontrolled hypertension. Lifestyle changes should be an anchor for the management of obesity-related hypertension; however, they are difficult to sustain. Drug therapy is often necessary to achieve blood pressure control. Diuretics, inhibitors of the renin-angiotensin system, and dihydropyridine calcium channel blockers are often used as first trio, with subsequent additions of mineralocorticoid receptor antagonists and/or dual alpha/beta blocking agents. While a number of agents are currently available, 50 % of hypertensive patients remain uncontrolled. A number of novel drug and invasive therapies are in development and hold significant potential for the effective management of obesity-related hypertension.
肥胖是一种全球性的流行疾病,随着肥胖的增加,其相关的合并症的患病率也在增加,尤其是未经控制的高血压。生活方式的改变应该是肥胖相关高血压管理的基础;然而,它们很难维持。药物治疗通常是实现血压控制所必需的。利尿剂、肾素-血管紧张素系统抑制剂和二氢吡啶钙通道阻滞剂通常被用作三联疗法,随后可以添加盐皮质激素受体拮抗剂和/或双重α/β阻断剂。虽然目前有许多药物可供选择,但仍有 50%的高血压患者血压未得到控制。目前正在开发许多新型药物和侵袭性治疗方法,它们对肥胖相关高血压的有效治疗具有重要潜力。